Last reviewed · How we verify

NCT04899180

Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis

Completed EARLY_PHASE1 Last updated 7 August 2024
What this trial tests

EARLY_PHASE1 trial testing 99mTc-PYP in Aortic Stenosis in 4 participants. Completed in 5 January 2024.

Timeline
14 July 2023
Primary endpoint
5 January 2024
5 January 2024

Quick facts

Lead sponsorMayo Clinic
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment4
Start date14 July 2023
Primary completion5 January 2024
Estimated completion5 January 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

75 and older, any sex, with Aortic Stenosis or Transthyretin Amyloidosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the prevalence of transthyretin cardiac amyloidosis (TTR-CA) among patients with moderate and severe aortic stenosis in Southeast Minnesota using 99mTc-PYP single-photon positive emission computed tomography with computed tomography (SPECT/CT).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Evaluation of the cardiac amyloidosis clinical pathway implementation: a real-world experience.
    Brons M, Muller SA, Rutten FH, van der Meer MG, et al · · 2022 · cited 24× · PMID 35919127 · DOI 10.1093/ehjopen/oeac011

Verify or expand the search:

Other trials of 99mTc-PYP

Trials testing the same drug.

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04899180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing